225 related articles for article (PubMed ID: 25374164)
21. A Quest for New Cancer Diagnosis, Prognosis and Prediction Biomarkers and Their Use in Biosensors Development.
Ramirez-Valles EG; Rodríguez-Pulido A; Barraza-Salas M; Martínez-Velis I; Meneses-Morales I; Ayala-García VM; Alba-Fierro CA
Technol Cancer Res Treat; 2020; 19():1533033820957033. PubMed ID: 33107395
[TBL] [Abstract][Full Text] [Related]
22. Novel Approaches in Ovarian Cancer Research against Heterogeneity, Late Diagnosis, Drug Resistance, and Transcoelomic Metastases.
Erol A; Niemira M; Krętowski AJ
Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31146417
[TBL] [Abstract][Full Text] [Related]
23. An overview of biomarkers for the ovarian cancer diagnosis.
Zhang B; Cai FF; Zhong XY
Eur J Obstet Gynecol Reprod Biol; 2011 Oct; 158(2):119-23. PubMed ID: 21632171
[TBL] [Abstract][Full Text] [Related]
24. Urine metabolite analysis offers potential early diagnosis of ovarian and breast cancers.
Slupsky CM; Steed H; Wells TH; Dabbs K; Schepansky A; Capstick V; Faught W; Sawyer MB
Clin Cancer Res; 2010 Dec; 16(23):5835-41. PubMed ID: 20956617
[TBL] [Abstract][Full Text] [Related]
25. Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care.
Graffeo R; Livraghi L; Pagani O; Goldhirsch A; Partridge AH; Garber JE
Breast Cancer Res Treat; 2016 Dec; 160(3):393-410. PubMed ID: 27734215
[TBL] [Abstract][Full Text] [Related]
26. High-throughput genomic technology in research and clinical management of breast cancer. Plasma-based proteomics in early detection and therapy.
Davis MA; Hanash S
Breast Cancer Res; 2006; 8(6):217. PubMed ID: 17184556
[TBL] [Abstract][Full Text] [Related]
27. Proteomic approaches in lung cancer biomarker development.
Cho JY; Sung HJ
Expert Rev Proteomics; 2009 Feb; 6(1):27-42. PubMed ID: 19210125
[TBL] [Abstract][Full Text] [Related]
28. Topoisomerase-I PS506 as a Dual Function Cancer Biomarker.
Zhao M; Gjerset RA
PLoS One; 2015; 10(8):e0134929. PubMed ID: 26248194
[TBL] [Abstract][Full Text] [Related]
29. [Establishment and verification of detecting multiple biomarkers for ovarian cancer by suspension array technology].
Zhao BB; Yang ZJ; Wang Q; Pan ZM; Zhang W; Li DR; Li L
Zhonghua Fu Chan Ke Za Zhi; 2016 Oct; 51(10):765-772. PubMed ID: 27788745
[No Abstract] [Full Text] [Related]
30. Biomarkers for screening, diagnosis, and monitoring of ovarian cancer.
Kobayashi E; Ueda Y; Matsuzaki S; Yokoyama T; Kimura T; Yoshino K; Fujita M; Kimura T; Enomoto T
Cancer Epidemiol Biomarkers Prev; 2012 Nov; 21(11):1902-12. PubMed ID: 22962405
[TBL] [Abstract][Full Text] [Related]
31. The clinical use of tumor makers in select cancers: are you confident enough to discuss them with your patients?
Sanchez Yamamoto D; Hallquist Viale P; Roesser K; Lin A
Oncol Nurs Forum; 2005 Sep; 32(5):1013-22; quiz 1023-4. PubMed ID: 16136199
[TBL] [Abstract][Full Text] [Related]
32. Multi-omics approaches for biomarker discovery in early ovarian cancer diagnosis.
Xiao Y; Bi M; Guo H; Li M
EBioMedicine; 2022 May; 79():104001. PubMed ID: 35439677
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the Prognostic Utility of the Diverse Molecular Data among lncRNA, DNA Methylation, microRNA, and mRNA across Five Human Cancers.
Xu L; Fengji L; Changning L; Liangcai Z; Yinghui L; Yu L; Shanguang C; Jianghui X
PLoS One; 2015; 10(11):e0142433. PubMed ID: 26606135
[TBL] [Abstract][Full Text] [Related]
34. Integrative genomic data mining for discovery of potential blood-borne biomarkers for early diagnosis of cancer.
Yang Y; Pospisil P; Iyer LK; Adelstein SJ; Kassis AI
PLoS One; 2008; 3(11):e3661. PubMed ID: 18987750
[TBL] [Abstract][Full Text] [Related]
35. [Screening pelvic tumours for hereditary risk of ovarian neoplasms, a cancer center experience].
Taïeb S; Rocourt N; Narducci F; Leblanc E; Adenis C; Fournier C; Doutrelant P; Peyrat JP; Vennin P
Bull Cancer; 2011 Feb; 98(2):113-9. PubMed ID: 21339094
[TBL] [Abstract][Full Text] [Related]
36. Ovarian cancer: biomarker proteomic diagnosis in progress.
Zhang Y; Guo B; Bi R
Appl Biochem Biotechnol; 2012 Oct; 168(4):910-6. PubMed ID: 22945560
[TBL] [Abstract][Full Text] [Related]
37. Cancer Proteomics and the Elusive Diagnostic Biomarkers.
Bradshaw RA; Hondermarck H; Rodriguez H
Proteomics; 2019 Nov; 19(21-22):e1800445. PubMed ID: 31172665
[TBL] [Abstract][Full Text] [Related]
38. Targeted proteomics of solid cancers: from quantification of known biomarkers towards reading the digital proteome maps.
Pernikářová V; Bouchal P
Expert Rev Proteomics; 2015; 12(6):651-67. PubMed ID: 26456120
[TBL] [Abstract][Full Text] [Related]
39. Implications of functional proteomics in breast cancer.
Chae YK; Gonzalez-Angulo AM
Oncologist; 2014 Apr; 19(4):328-35. PubMed ID: 24664486
[TBL] [Abstract][Full Text] [Related]
40. Lung cancer molecular mutations and abnormal glycosylation as biomarkers for early diagnosis.
Yang S; Xia J; Yang Z; Xu M; Li S
Cancer Treat Res Commun; 2021; 27():100311. PubMed ID: 33465560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
